Medical Dosimetry is a distinguished journal published by Elsevier Science Inc, dedicated to the advancing field of medical dosimetry and its applications within oncology, radiology, and nuclear medicine. With its ISSN 0958-3947 and E-ISSN 1873-4022, this journal serves as a crucial resource for researchers and professionals aiming to enhance their understanding of radiation treatment planning and dosage calculations. Encompassing a comprehensive range of topics from clinical dosimetry to technology assessment, Medical Dosimetry has been disseminating significant findings since its establishment in 1988, contributing to the continuous development of best practices in patient care and safety. The journal currently holds a Q3 ranking in various categories, reflecting its pivotal role in the research community, while not currently offering open access, it remains an essential reference for scholars advancing the techniques utilized in medical imaging and treatment. By fostering a platform for high-quality research, it aims to bridge the gap between theoretical studies and clinical applications, making it a vital addition to any medical library.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.

European Urology Open Science is a premier open-access journal dedicated to advancing the field of urology through publishing high-quality, peer-reviewed research. Published by ELSEVIER in the Netherlands, this journal is recognized for its significant contribution to the medical community, boasting an impressive Q1 ranking in Urology for 2023, indicative of its influence and the quality of research it disseminates. With a focus on innovative studies and interdisciplinary approaches, the European Urology Open Science plays a pivotal role in fostering knowledge exchange and promoting clinical best practices. Researchers, professionals, and students alike benefit from its accessible research format, facilitating a broader dissemination of urological advancements. This journal embraces the Open Access model, ensuring that pioneering findings are readily available to the global scientific community, further enhancing collaboration and knowledge sharing within the field.

Case Reports in Oncological Medicine is a distinguished open-access journal published by HINDAWI LTD, dedicated to disseminating valuable insights and findings in the field of oncology. Since its inception in 2011, this journal has aimed to provide a unique platform for the publication of detailed case reports that contribute to our understanding of cancer diagnosis, treatment, and management. With a specific focus on sharing clinical experiences and outcomes, it seeks to engage researchers, healthcare professionals, and students who are committed to advancing oncological knowledge and improving patient care. Although coverage in Scopus was discontinued from 2014 to 2017, the journal currently holds a rank of #232/323 in Medicine - Oncology, placing it within the 28th percentile. Researchers interested in making their work accessible can benefit from the journal's open-access model, allowing greater visibility and citation potential within the scientific community. The journal is positioned as an important resource for those looking to stay updated on the latest case studies and innovations in oncological medicine.

International Journal of Radiation Oncology Biology Physics, published by Elsevier Science Inc, is a premier academic journal that has played a critical role in advancing the field of radiation oncology since its inception in 1975. With an impressive impact factor and recognition as a Q1 journal across multiple categories such as Cancer Research, Oncology, and Radiology, this journal serves as a vital resource for researchers, clinicians, and students dedicated to understanding and improving cancer treatment modalities. Its multifaceted scope encompasses original research, reviews, and innovative clinical studies, fostering a deeper understanding of the interplay between radiation, biology, and oncology. With a remarkable ranking in Scopus, including a top position in Radiation Physics and an elite percentile in Oncology, IJROBP remains at the forefront of scientific discovery and innovation in the management of cancer. A traditional subscription model ensures high-quality, peer-reviewed content, providing invaluable insights that continue to advance the standards of care and research in radiation oncology.

The Japanese Journal of Radiology, published by SPRINGER, serves as a premier platform for disseminating cutting-edge research and clinical advancements in the fields of radiology, nuclear medicine, and imaging. With an ISSN of 1867-1071 and E-ISSN 1867-108X, this journal has established itself as a vital resource for practitioners, researchers, and students alike. Renowned for its high-quality peer-reviewed articles, it currently enjoys a respectable impact factor within the Q2 category of Scopus rankings, placing it in the 69th percentile among 333 journals in its field. The journal has seen consistent convergence of research from 2009 to 2024, further underscoring its commitment to advancing the understanding of radiological practices. Importantly, the journal offers Open Access options to facilitate widespread dissemination of knowledge, ensuring that vital research reaches its audience without barriers. Addressed in Japan, the Japanese Journal of Radiology plays a critical role in enhancing the global discourse on medical imaging, making it an essential resource for anyone engaged in this dynamic field.

Brachytherapy, published by ELSEVIER SCIENCE INC, serves as a pivotal journal in the realms of Oncology and Radiology, Nuclear Medicine, and Imaging. With an ISSN of 1538-4721 and an E-ISSN of 1873-1449, the journal disseminates cutting-edge research and advancements from 2002 to 2024, focusing on the innovative field of brachytherapy. Although classified in the Q3 category for Oncology and Q2 for Radiology, Nuclear Medicine, and Imaging based on the 2023 quartile rankings, it continues to make significant contributions to clinical practice and methodology. Brachytherapy holds a respectable position in Scopus, ranking #155/333 and #234/404 in its respective categories, which reflects its importance and relevance to the scientific community. This journal is indispensable for researchers, healthcare professionals, and students looking to stay abreast of the latest techniques and therapeutic approaches in cancer treatment and imaging practices.

Radiotherapy and Oncology is a leading peer-reviewed journal published by Elsevier Ireland Ltd, focusing on the vital fields of hematology, oncology, and radiology. With an impressive impact factor and ranking in the top quartiles (Q1) of its categories as of 2023, it is recognized for disseminating high-quality research that contributes significantly to advancements in cancer treatment and patient care. The journal, which has been in circulation since 1983, aims to provide a platform for original research articles, reviews, and clinical studies that explore the latest innovations in radiotherapeutic technologies and oncology practices. This journal is essential for researchers, healthcare professionals, and students who are dedicated to improving cancer therapies and outcomes. Although it does not offer open access, the wealth of information contained within its pages supports continued education and development in these crucial medical fields.

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.

Reports of Practical Oncology and Radiotherapy is a distinguished open-access journal dedicated to advancing the fields of oncology, radiotherapy, and cancer research. Published by VIA MEDICA since 2001, this journal serves as a critical platform for disseminating innovative research and practical findings that impact clinical practices and patient outcomes. With an emphasis on fostering collaboration and knowledge exchange among researchers, clinicians, and students, the journal has positioned itself within the Q3 and Q4 categories of renowned directories in oncology, radiology, and nuclear medicine as of 2023. Based in Gdansk, Poland, it provides unrestricted access to its articles, ensuring that crucial research reaches a wide audience. This dedication to open access reflects the journal's commitment to transparency and innovation in the fight against cancer, making it an invaluable resource in this vital field of study.